For: | Sugimoto M, Nishino M, Kodaira C, Yamade M, Uotani T, Ikuma M, Umemura K, Furuta T. Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy. World J Gastroenterol 2011; 17(14): 1858-1865 [PMID: 21528060 DOI: 10.3748/wjg.v17.i14.1858] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v17/i14/1858.htm |
Number | Citing Articles |
1 |
Mitsushige Sugimoto, Naohito Shirai, Masafumi Nishino, Chise Kodaira, Takahiro Uotani, Shu Sahara, Hitomi Ichikawa, Takuma Kagami, Ken Sugimoto, Takahisa Furuta. Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese. European Journal of Clinical Pharmacology 2014; 70(9): 1073 doi: 10.1007/s00228-014-1713-y
|
2 |
Katsuhiko Iwakiri, Yasuhiro Fujiwara, Noriaki Manabe, Eikichi Ihara, Shiko Kuribayashi, Junichi Akiyama, Takashi Kondo, Hiroshi Yamashita, Norihisa Ishimura, Yuichi Kitasako, Katsunori Iijima, Tomoyuki Koike, Nobuo Omura, Tsutomu Nomura, Osamu Kawamura, Shuichi Ohara, Soji Ozawa, Yoshikazu Kinoshita, Satoshi Mochida, Nobuyuki Enomoto, Tooru Shimosegawa, Kazuhiko Koike. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. Journal of Gastroenterology 2022; 57(4): 267 doi: 10.1007/s00535-022-01861-z
|
3 |
Benjamin D. Gold, Betsy Pilmer, Jaroslaw Kierkuś, Barbara Hunt, Maria Claudia Perez, David Gremse. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease. Digestive Diseases and Sciences 2017; 62(11): 3059 doi: 10.1007/s10620-017-4743-3
|
4 |
Sanjit Kumar, Manjari Singh, Jitendra K. Rawat, Swetlana Gautam, Shubhini A. Saraf, Gaurav Kaithwas. Effect of rutin against gastric esophageal reflux in experimental animals. Toxicology Mechanisms and Methods 2014; 24(9): 666 doi: 10.3109/15376516.2014.961215
|
5 |
H. Kikuchi, S. Fukuda, T. Koike, Y. Shimodaira, K. Watanabe, M. Saito, K. Nakagawa, W. Hatta, A. Masamune, K. Iijima. Association of residual gastric acid secretion with persistent symptoms in gastroesophageal reflux disease patients receiving standard-dose proton pump inhibitor therapy. Esophagus 2021; 18(2): 380 doi: 10.1007/s10388-020-00765-2
|
6 |
Chingching Foocharoen, Kitti Chunlertrith, Pisaln Mairiang, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Suwassa Namvijit, Orathai Wantha, Ratanavadee Nanagara. Effectiveness of add-on therapy with domperidonevsalginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. Rheumatology 2017; 56(2): 214 doi: 10.1093/rheumatology/kew216
|
7 |
T E Habesoglu, M Habesoglu, C Kalaycik, A Tek, M Surmeli, E Egeli. Gastroesophageal reflux disease and tympanoplasty surgical outcome: is there a relationship?. The Journal of Laryngology & Otology 2012; 126(6): 580 doi: 10.1017/S0022215112000461
|
8 |
Kayo Akutagawa, Ryuichi Iwakiri, Megumi Hara, Kazuma Fujimoto, Yasuhiro Fujiwara, Masahiko Inamori, Junji Tanaka, Tomohiko Shimatani, Junichi Akiyama, Takashi Ando, Noriaki Manabe, Fukunori Kinjo, Ryuzo Deguchi, Motoyasu Kusano. Risk factors for low response to proton-pump inhibitor treatment in reflux esophagitis and non-erosive reflux disease evaluated by the frequency scale for the symptoms of gastroesophageal reflux disease. Esophagus 2015; 12(3): 225 doi: 10.1007/s10388-014-0477-x
|
9 |
Nunzio Ranaldo, Giuseppe Losurdo, Andrea Iannone, Mariabeatrice Principi, Michele Barone, Massimo De Carne, Enzo Ierardi, Alfredo Di Leo. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease. Cell Death & Disease 2017; 8(9): e3040 doi: 10.1038/cddis.2017.436
|
10 |
Chingching Foocharoen, Kitti Chunlertrith, Pisaln Mairiang, Ajanee Mahakkanukrauh, Siraphop Suwannaroj, Suwassa Namvijit, Orathai Wantha, Ratanavadee Nanagara. Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-57636-0
|
11 |
Hitomi Ichikawa, Mitsushige Sugimoto, Ken Sugimoto, Akira Andoh, Takahisa Furuta. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. Journal of Gastroenterology and Hepatology 2016; 31(4): 716 doi: 10.1111/jgh.13233
|
12 |
M. Sugimoto, N. Shirai, M. Nishino, C. Kodaira, T. Uotani, M. Yamade, S. Sahara, H. Ichikawa, K. Sugimoto, H. Miyajima, T. Furuta. Rabeprazole 10 mg q.d.s. decreases 24‐h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Alimentary Pharmacology & Therapeutics 2012; 36(7): 627 doi: 10.1111/apt.12014
|
13 |
Katsuhiko Iwakiri, Yoshikazu Kinoshita, Yasuki Habu, Tadayuki Oshima, Noriaki Manabe, Yasuhiro Fujiwara, Akihito Nagahara, Osamu Kawamura, Ryuichi Iwakiri, Soji Ozawa, Kiyoshi Ashida, Shuichi Ohara, Hideyuki Kashiwagi, Kyoichi Adachi, Kazuhide Higuchi, Hiroto Miwa, Kazuma Fujimoto, Motoyasu Kusano, Yoshio Hoshihara, Tatsuyuki Kawano, Ken Haruma, Michio Hongo, Kentaro Sugano, Mamoru Watanabe, Tooru Shimosegawa. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. Journal of Gastroenterology 2016; 51(8): 751 doi: 10.1007/s00535-016-1227-8
|
14 |
M. Tabib, H. Zolgharnein, M. Mohammadi, M.A. Salari-Aliabadi, A. Qasemi, S. Roshani, H. Rajabi-Maham, F. Frootan. mtDNA variation of the critically endangered hawksbill turtle (Eretmochelys imbricata) nesting on Iranian islands of the Persian Gulf. Genetics and Molecular Research 2011; 10(3): 1499 doi: 10.4238/vol10-3gmr1148
|